TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05856162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENRICH pilot intervention (full intervention)
Description: The full ENRICH pilot intervention will consist of content related to diet, physical activity, stress/mental health, sleep, tobacco cessation, and child health. The investigators will use an adapted version of the Mothers and Babies stress management intervention to address mental health, an adapted version of the HEALTH curriculum to address diet/physical activity, and an adapted version of the INSIGHT curriculum to address child health.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ENRICH pilot intervention (partial intervention: only diet and physical activity)
Description: The partial ENRICH intervention will focus only on diet and physical activity.
Study: NCT06647550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD-6277 100mg
Description: PO, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD-6277 50mg
Description: PO, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD-6277 25mg
Description: PO, QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO, QD
Study: NCT06521268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decongestive treatment
Description: Decongestive treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decongestive treatment
Description: Decongestive treatment
Study: NCT06655324

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V350A
Description: Vaccination administered via intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V350B
Description: Vaccination administered via intramuscular injection
Study: NCT05008315

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham
Description: sham
Study: NCT06655324

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaccination administered via intramuscular injection
Study: NCT06661733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462 orally.
Study: NCT06660732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilonacept
Description: 320 mg subcutaneous (SC) loading dose delivered as two 2-mL, subcutaneous injections of 160 mg on the same day at different anatomical sites followed by once weekly 160 mg SC doses.
Study: NCT06670768

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stress Dynamic MPI SPECT
Description: BMI standardized radiopharmaceutical injection in pharmacological stress (dipyridamole or adenosine) is performed under the SPECT camera to record the temporal distribution of the activity. A one-day protocol and multi-pinhole collimator are used.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stress Static MPI SPECT
Description: 30-60 minutes after stress dynamic SPECT imaging is performed, an ECG-gated static SPECT MPI is conducted with a conventional LEHR collimator.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rest Dynamic MPI SPECT
Description: 3 hours after the stress phase, the rest phase is also recorded. A radiopharmaceutical injection with a three-fold dose at rest is performed under the SPECT camera to record the temporal distribution of the activity. A one-day protocol and multi-pinhole collimator are used.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rest Static MPI SPECT
Description: 30-60 minutes after rest, dynamic SPECT imaging is performed, and an ECG-gated static SPECT MPI is conducted with a conventional LEHR collimator.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac CT
Description: Within 30 days of MPI SPECT imaging, a cardiac CT is performed for every patient, including a native calcium-scoring scan and a coronary CT angiography as a reference standard. A photon-counting detector CT is used.
Study: NCT05150925

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cast treatment
Description: Dorsal cast placed in OR

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate mobilization
Description: Immediate mobilization postoperatively without casting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volar plating
Description: Volar plating of distal radius fracture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volar plating
Description: Volar plating of distal radius fracture
Study: NCT06516289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1167
Description: a highly selective PARP1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1167
Description: a highly selective PARP1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1167
Description: a highly selective PARP1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1167
Description: a highly selective PARP1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1167
Description: a highly selective PARP1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: a humanised anti-programmed death-1 (anti PD-1) antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: a humanised anti-programmed death-1 (anti PD-1) antibody
Study: NCT06668025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MxA tests
Description: Whole blood samples will be collected on Days 1, 4, 7, and 10 for MxA testing. MxA measurements on Days 4, 7, and 10 will be performed only for patients still hospitalized on antiviral thearpy or at the attending physician's discretion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MxA feedback
Description: MxA results will be reported to the attending physician within 4 hours, along with MxA-based antiviral treatment guidelines.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up at Day 30
Description: A telephone visit will be conducted on or around Day 30 for study participants who are discharged, to collect information on antiviral usage, recurrence infection, readmissions, and additional medical visits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up at Day 30
Description: A telephone visit will be conducted on or around Day 30 for study participants who are discharged, to collect information on antiviral usage, recurrence infection, readmissions, and additional medical visits.
Study: NCT04940624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat mini-tablets or tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soticlestat placebo-matching mini-tablets or tablets.
Study: NCT06669611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab combined GP chemotherapy
Description: Camrelizumab was intravenously given at dose of 200 mg on day 1. The GP regimen included gemcitabine administered at a dose of 1 g/m2 on day 1 and day 8, cisplatin at a dose of 80 mg/m2 on day 1.Q3W 1 cycle, 4-6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab combined TPC chemotherapy
Description: Camrelizumab was intravenously given at dose of 200 mg on day 1. The TPC regimen included nab-paclitaxel administered at a dose of 200 mg/m2 on day 1, cisplatin at a dose of 60 mg/m2 on day 1, and capecitabine at a dose of 1000 mg/m2, taken orally twice a day on days 1 to 14, for each cycle. Q3W 1 cycle, 4-6 cycles.
Study: NCT06539429

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-301
Description: Administration on Day 1
Study: NCT05215197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intracochlear platelet rich fibrin administration
Description: intracochlear platelet rich fibrin administration during routine cochlear implantation surgery
Study: NCT06530394

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Greek yogurt
Description: Whole food dairy products, such as Greek yogurt (GY), offer a high quality, nutrient-dense snack, high in bone-supporting ingredients, including protein, calcium, and phosphorus. These nutrients are crucial to the structural integrity and strength of bone, i.e., the collagen and hydroxyapatite matrices.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Greek yogurt
Description: Whole food dairy products, such as Greek yogurt (GY), offer a high quality, nutrient-dense snack, high in bone-supporting ingredients, including protein, calcium, and phosphorus. These nutrients are crucial to the structural integrity and strength of bone, i.e., the collagen and hydroxyapatite matrices.
Study: NCT06677502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: Patients were randomized into two groups: CBL - patients treated with cerebrolysin at the daily dose of 50 mL, and K - control patients treated without cerebrolysin. Cerebrolysin was administrated intravenously on the day the delirium was detected and then for seven consecutive days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution - IV
Description: Patients enrolled in group K received the infusion of 0.9% Saline solution at a volume of 250 mL.
Study: NCT05788081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: golcadomide
Description: BMS-986369 is an orally administered Cereblon-modulating compound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: golcadomide
Description: BMS-986369 is an orally administered Cereblon-modulating compound
Study: NCT06608277

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group A active comparator
Description: Group A placebo comparator. Stellate Ganglion Block plus placebo (.9 normal saline) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group B active comparator
Description: Active Comparator: Group B = Sham Stellate Ganglion Block plus ketamine infusion

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Group C Experimental
Description: Group C experimental Stellate Ganglion Block plus ketamine infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group D Placebo Comparator
Description: Group D Placebo Comparator: Sham Stellate Ganglion Block plus placebo normal saline
Study: NCT06623409

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GARDASIL®9 (G9)
Description: Suspension administered via intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V540B
Description: Experimental vaccine and adjuvant administered via IM injection
Study: NCT06682416

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In the context of epidural analgesia, the temperature of the local anesthetic solution is elevated to 37°C utilizing a blood transfusion and infusion warmer.
Description: For the observation group, after reactivating the analgesic pump's exhaust procedure to clear the air from the tubing, the output tubing of the analgesic pump is first connected to the epidural catheter. Following this, a blood transfusion and infusion warmer (manufactured by Barkey GmbH \& Co. KG., Germany, model S-line, with the national medical device registration number 20182450063) is used to preheat the output tubing of the analgesic pump until it reaches the predetermined temperature of 37°C.~For the control group, after reactivating the analgesic pump's exhaust procedure to remove air from the tubing, the output tubing of the analgesic pump is connected to the epidural catheter without preheating the output tubing using a blood transfusion and infusion warmer, maintaining room temperature (23°C).
Study: NCT06688955

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy with Bacteriological Controlled Water
Description: Patient with coloscopy which used Bacteriological Controlled Water : Collection of 250 ml of bacteriologically controlled water from the wash bottle at the end of each water-assisted colonoscopy to test for enterobacteria and fecal streptococci
Study: NCT06690983

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-S16/T807
Description: Each subject receive a single intravenous injection of 18F-S16/T807, and undergo PET/CT or MRI imaging within the specificed time.
Study: NCT06691685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESO-T01 Injection
Description: ESO-T01 Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries an effective BCMA-targeted CAR. ESO-T01 can be administered intravenously and produce CAR-T in vivo.
Study: NCT06611540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of a cervical sample by clinician

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Biopsy
Description: Undergo cervical biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colposcopy
Description: Undergo colposcopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endocervical Curettage
Description: Undergo endocervical curettage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision
Description: Undergo cervical excisional procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HPV Self-Collection
Description: Undertake self-collection of vaginal sample

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus Test
Description: Undergo HPV testing of self-collected vaginal samples and cervical samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05788081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML
Description: Nivolumab is a fully humanised IgG4 blocking monoclonal antibody against PD-1.
Study: NCT04795245

Intervention type: DRUG
Intervention: afatinib
Description: afatinib
Study: NCT06320860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kidney Stone Retrieval
Description: Using FlexStone Basket aimability to retrieve kidney stones
Study: NCT05613426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Description: Very early use of Rosuvastatin before primary PCI in anterior STEMI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20 mg
Description: Very early use of Rosuvastatin before primary PCI in anterior STEMI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA]
Description: Very early use of Evolocumab before primary PCI in anterior STEMI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA]
Description: Very early use of Evolocumab before primary PCI in anterior STEMI
Study: NCT04817969

Intervention type: DEVICE
Group type: OTHER
Intervention: Zimmer Biomet Persona Ti-Nidium Total Knee System
Description: Primary Knee Total Arthroplasty
Study: NCT05303194

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient Priorities Care (PPC) Approach
Description: First, identify patient priorities, and second align care received with those priorities.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adapted PPC
Description: First, identify patient priorities, and second align care received with those priorities.
Study: NCT04996316

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Health record reviewed

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Health record reviewed

Intervention type: OTHER
Intervention: Interview
Description: Participate in interview

Intervention type: OTHER
Intervention: Interview
Description: Participate in interview

Intervention type: OTHER
Intervention: Media Intervention
Description: Use MammoScreen

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey

Intervention type: OTHER
Intervention: Training and Education
Description: Undergo training
Study: NCT06695897

Intervention type: DRUG
Intervention: Dupilumab
Description: This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
Study: NCT06630039

Intervention type: OTHER
Intervention: Scale validity and reliability
Description: The aim of this study is to adapt the Short-Western Ontario Rotator Cuff Disability Index (SHORTWORC) to Turkish society in patients with rotator cuff injury and to make its validity and reliability in Turkish. It has 7 questions. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
Study: NCT05788081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is a chimeric anti-CD20 antibody containing human IgG lambda and kappa constant regions with murine variable regions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is a chimeric anti-CD20 antibody containing human IgG lambda and kappa constant regions with murine variable regions
Study: NCT06701357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR-CHOP+PD1 inhibitor
Description: Rituximab 375 mg/m2 D1； Cyclophosphamide 750mg/m2 D2； Doxorubicin 50mg/m2 D2； Vincristine 1.4 mg/m2 D2； Prednisone 60 mg/m2 D2-6； Chidamide 20mg/d D1,4,8,11； PD1 200mg D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR-CHOP + Orelabrutinib
Description: Rituximab 375 mg/m2 D1； Cyclophosphamide 750mg/m2 D2； Doxorubicin 50mg/m2 D2； Vincristine 1.4 mg/m2 D2； Prednisone 60 mg/m2 D2-6； Chidamide 20mg/d D1,4,8,11； Orelabrutinib 150mg/qd D1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR-CHOP + decitabine
Description: Rituximab 375 mg/m2 D1； Cyclophosphamide 750mg/m2 D2； Doxorubicin 50mg/m2 D2； Vincristine 1.4 mg/m2 D2； Prednisone 60 mg/m2 D2-6； Chidamide 20mg/d D1,4,8,11； Decitabine 10mg/m2 D-5 - -1
Study: NCT06720662

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Icosapent-ethyl ester capsules
Description: Icosapent-ethyl ester (4.0 g of EPA) taken twice a day (2.0 g/day x 2) for six months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil Control
Description: Corn oil twice a day (2.0 g/day x 2) for six months.
Study: NCT06720155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleeper stretch
Description: Participants will complete their regularly scheduled workout activities over 8 weeks, with the addition of the sleeper stretch into the dynamic warm-up. Participants will be instructed to lie side-lying with the dominant arm downward, the trunk rotated posteriorly 20 to 30°, the shoulder raised to 90°, the elbow flexed to 90°, and both knees semi-flexed to ensure stability. Participants will then be asked to use the opposite hand to grasp the dominant hand below the wrist and gradually internally rotate the forearm towards the floor; (i.e., the participant will perform passive internal rotation with the opposite arm). This stretch position will be completed on both sides. Participants will be instructed to complete 2 sets of 10 repetitions for each arm and hold the position for \~2 seconds.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard workout
Description: Participants will complete their regularly programmed dynamic warm-ups before scheduled workout for 8 weeks.
Study: NCT06724757

Intervention type: OTHER
Intervention: Health questionnaire
Description: The intervention involves the completion and analysis of an online questionnaire designed to assess the health (mental, physical, social) of caregivers aged 50 and over in Quebec. This assessment is based on a combination of questionnaires (CARE, 4-item Zarit scale, 4-item GDS, 3-item UCLA loneliness scale, etc.).
Study: NCT06733181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REMINDER intervention
Description: The REMINDER intervention includes 20 face-to-face group sessions, each approximately 60 to 75 minutes, held twice a week over ten weeks. This program aims to optimize memory, attention, executive function, and emotional regulation while promoting lifestyle habits that protect the aging brain. The sessions include brain health education, cognitive exercises, compensatory memory strategies, training for managing personally relevant goals (with goal setting), and stress management techniques (compassion-based therapies, relaxation methods, and mindfulness). As for the structure of the sessions, each starts with a mindfulness exercise and concludes with a review of the homework assignments. Every session includes a psychoeducation component focused on a specific topic, a time for sharing and reflection, and a practical activity.